The global allergy diagnostics and therapeutics market is undergoing rapid transformation as the prevalence of allergic diseases continues to increase worldwide. Allergic rhinitis, asthma, food allergies, drug allergies, and other hypersensitivity conditions are becoming increasingly common amid urbanization, environmental pollution, changing lifestyles, and greater exposure to indoor and outdoor allergens. At the same time, improvements in diagnostic technologies and the development of advanced therapeutics are creating new opportunities across the healthcare industry.
Key Market Highlights
• 2025 Market Size: USD 37.1 billion
• 2026 Market Size: USD 40.2 billion
• 2033 Projected Market Size: USD 78.0 billion
• CAGR: 10.0% (2026–2033)
• Key Growth Factors: Rising allergy prevalence, technological advancements, new product launches, and increasing adoption of immunotherapy drugs
Market Segmentation Overview
• By Type: The therapeutics segment dominated the market with a 82.9% revenue share in 2025. The segment benefits from the continued need to manage allergic symptoms and severe allergic reactions. Meanwhile, the diagnostics segment is expected to register the fastest CAGR during the forecast period as healthcare providers increasingly emphasize accurate and early identification of allergic conditions.
• By Allergen Type: Inhaled allergies accounted for the largest market share, reaching 49.9% in 2025. Increasing exposure to air pollution, industrial emissions, dust mites, mold spores, pet dander, and pollen is contributing to the growing incidence of respiratory allergies. Drug allergies are expected to experience faster growth during the forecast period.
• By Test Type: In vitro tests represented the leading segment with a 52.3% market share in 2025. Blood-based testing can identify allergen-specific immunoglobulin E (IgE) and offers advantages such as minimal invasiveness, convenience, and suitability for different types of allergies.
Key Growth Drivers
Rising Prevalence of Allergic Diseases: The increasing incidence of allergies is one of the primary factors supporting industry expansion. Greater exposure to environmental contaminants, indoor and outdoor air pollution, industrial activity, and urbanization is contributing to the growing prevalence of allergic conditions. Allergies are also more common in urban environments, where exposure to environmental pollutants can be higher.
Advancement in Immunotherapy: The development of therapeutically advanced drugs is creating new opportunities in allergy treatment. Immunotherapy is gaining importance because it can address underlying allergic responses rather than focusing only on temporary symptom relief. In February 2024, the U.S. FDA approved Xolair (omalizumab) for certain adults and children aged one year and older with IgE-mediated food allergy, reducing the risk of allergic reactions caused by accidental exposure to more than one food.
Growing Demand for IVD Testing: Increasing demand for in vitro diagnostic testing is another important growth factor. In vitro blood tests are used to identify food, inhalation, skin, and medication allergies. Their minimally invasive nature, ease of use, and cost-effectiveness are encouraging wider adoption across diagnostic laboratories and healthcare facilities.
Technology Is Reshaping Allergy Diagnosis
Technology is becoming a central component of the allergy diagnostics industry. Laboratories and healthcare providers are increasingly adopting molecular diagnostics, multiplex assays, component-resolved diagnostics, automated testing systems, and AI-enabled platforms to improve testing precision.
Component-resolved diagnostics can provide more detailed information about specific allergen components, helping clinicians understand sensitization patterns and make better-informed treatment decisions. The integration of artificial intelligence is also creating opportunities for improved interpretation of diagnostic results and more personalized allergy management.
Automation is another important development. Increasing laboratory workloads and demand for efficient testing are encouraging the adoption of automated immunoassay platforms. These systems can streamline workflows while supporting consistent and efficient processing of allergy tests.
Diagnostics Segment Creates New Opportunities
Although therapeutics currently represent the dominant component of the market, diagnostics is expected to register the highest CAGR during the forecast period. This trend reflects the growing emphasis on precise identification of allergic sensitivities and the need to distinguish between different allergen triggers.
New product development is further strengthening this segment. In April 2025, Beckman Coulter Life Sciences launched a next-generation Basophil Activation Test designed for research use. The technology enables food allergy identification through a blood draw, potentially reducing the need for direct allergen exposure during testing.
The growing focus on early detection and personalized healthcare is expected to encourage additional investments in advanced allergy testing platforms.
Inhaled Allergies Remain a Major Focus
The inhaled allergies segment held a 49.9% revenue share in 2025, making it the largest allergen category. Industrialization, air pollution, changing climate patterns, longer pollen seasons, and increased exposure to indoor allergens are contributing to the growing incidence of respiratory allergies.
Improved diagnostic technologies are helping clinicians identify specific inhaled triggers. Molecular allergen profiling and component-resolved diagnostics are providing greater insight into individual sensitization patterns, supporting more targeted treatment strategies.
At the same time, the growing awareness of allergies among patients and increased availability of testing facilities are contributing to higher diagnosis rates.
Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.
Regional Dynamics
North America: North America dominated the global allergy diagnostics and therapeutics market with a 36.6% revenue share in 2025. The region benefits from established healthcare infrastructure, strong regulatory frameworks, high allergy prevalence, significant R&D investment, and widespread adoption of innovative diagnostic and therapeutic technologies. The U.S. held the largest country-level market share in 2025.
The region is also witnessing increasing clinical research activity. In October 2025, RAPT Therapeutics initiated a Phase 2b clinical trial for ozureprubart to investigate its potential for treating IgE-mediated food allergies at approximately 30 locations across the U.S. and Canada.
Asia Pacific: The region presents significant future opportunities as healthcare infrastructure expands and awareness of allergy diagnosis and treatment increases. Urbanization, environmental pollution, changing lifestyles, and greater healthcare expenditure are expected to support demand for allergy diagnostics and therapeutics.
Competitive Landscape
The allergy diagnostics and therapeutics industry features established pharmaceutical, biotechnology, and diagnostic companies competing through product development, clinical research, strategic partnerships, and technology innovation.
Key companies profiled by Grand View Research include bioMérieux, Thermo Fisher Scientific, Danaher Corporation, Omega Diagnostics, Hitachi Chemical Diagnostics, Stallergenes Greer, Siemens Healthcare, Lincoln Diagnostics, Hycor Biomedical, HOB Biotech Group, and Alcon Laboratories.
The industry is also experiencing moderate merger and acquisition activity. In January 2024, ALK acquired AllerQuest's U.S. business holdings, including PRE-PEN, an FDA-approved skin test used for diagnosing penicillin allergies.
Explore our dedicated business services:
• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.
About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.
